Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis

Pancreas

Volumn 35, Issue 2, 2007, Pages 114-119

  Kumar, Yogesh ^a   Gurusamy, Kurinchi ^a   Pamecha, Vineet ^a   Davidson, Brian R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Exocrine pancreatic cancer; Pancreatic neoplasm; Pyruvate kinase; TuM2 PK; Tumor M2 pyruvate kinase

Indexed keywords

CA 19-9 ANTIGEN; PYRUVATE KINASE; TUMOR M2 PYRUVATE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CONFIDENCE INTERVAL; DATA BASE; DIAGNOSTIC ACCURACY; EMBASE; HUMAN; MEDLINE; PANCREAS CANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCISEARCH;

CA-19-9 ANTIGEN; CLINICAL TRIALS; HUMANS; PANCREATIC NEOPLASMS; PYRUVATE KINASE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447503504     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e3180537237     Document Type: Article

References (38)

1. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485-489.
2. Cancer Research UK. 2006. UK Pancreatic Cancer Statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/pancreas. Accessed October, 24, 2006.
3. Wood HE, Gupta S, Kang JY, et al. Pancreatic cancer in England and Wales 1975-2000: patterns and trends in incidence, survival and mortality. Aliment Pharmacol Ther. 2006;23:1205-1214.
4. Vogt DP. Pancreatic cancer: a current overview. Curr Surg. 2000;57:214-220.
5. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer. 1985;56:397-402.
6. Kau SY, Shyr YM, Su CH, et al. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg. 1999;188:415-420.
7. Osswald BR, Klee FE, Wysocki S. The reliability of highly elevated CA 19-9 levels. Dis Markers. 1993;11:275-278.
8. McLaughlin R, O'Hanlon D, Kerin M, et al. Are elevated levels of the tumour marker CA19-9 of any clinical significance? - An evaluation. Ir J Med Sci. 1999;168:124-126.
9. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26:474-479.
10. Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300-308.
11. Mazurek S, Grimm H, Boschek CB, et al. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr. 2002;87(suppl 1):S23-S29.
12. Cerwenka H, Aigner R, Bacher H, et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res. 1999;19:849-851.
13. Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res. 2000;20:4965-4968.
14. Oremek GM, Eigenbrodt E, Radle J, et al. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res. 1997;17:3031-3033.
15. Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res. 2003;23:5089-5093.
16. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res. 2000;20:4961-4964.
17. Siriwardana HPP, King NKK, France MW, et al. Plasma tumour-M2-pyruvate kinase and serum carbohydrate antigen for the preoperative diagnosis of pancreatic cancer. Br J Surg. 2005;92 (suppl 1):100. [abstract].
18. Siriwardana P, King N, France M, et al. Prospective evaluation of the diagnostic accuracy of plasma tumour M2-pyruvate kinase (TuM2-PK) and serum carbohydrate antigen (CA19-9) in periampullary cancer. Gastroenterology. 2005;128(suppl 2):A472-A473. [abstract].
19. Ventrucci M, Cipolla A, Racchini C, et al. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci. 2004;49:1149-1155.
20. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061-1066.
21. Rutjes AW, Reitsma JB, Di NM, et al. Evidence of bias and variation in diagnostic accuracy studies. CMAJ. 2006;174:469-476.
22. Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in context. 2nd ed. London: BMJ Publishing Group; 2001:248-282.
23. Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129-1135.
24. StatsDirect Statistical Software Version 2.5.6. Cheshire, UK: StatsDirect; 2005.
25. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6:341-350.
26. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
28. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
29. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606-621.
30. Habbe N, Langer P, Sina-Frey M, et al. Familial pancreatic cancer syndromes. Endocrinol Metab Clin North Am. 2006;35:417-430.
31. Lowenfels AB, Maisonneuve P, Dimagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442-446.
32. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433-1437.
33. Okusaka T, Yamada T, Maekawa M. Serum tumor markers for pancreatic cancer: the dawn of new era? JOP. 2006;7:332-336.
34. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3868.
35. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386-2392.
36. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442-446.
37. Li Z, Sclabas GM, Peng B, et al. Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer. 2004;101:58-65.
38. Rosty C, Ueki T, Argani P, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol. 2002;160:45-50.